Welcome to our dedicated page for Enovis SEC filings (Ticker: ENOV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Enovis Corporation filings document the formal disclosures of a public medical technology company with Reconstructive and Prevention & Recovery operations. Recent Form 8-K reports cover quarterly and annual results, furnished earnings releases, conference presentation materials and Regulation FD disclosures tied to management presentations.
The filing record also includes proxy materials for annual meeting governance, board and executive compensation matters, executive transition disclosures, and material financing agreements. Enovis filings describe credit facilities, leverage covenants, guarantor arrangements, senior unsecured convertible notes references, financial condition, segment performance and related risk and governance subjects.
Enovis Corporation’s common stock is the subject of a Schedule 13G filed by Rubric Capital Management LP and David Rosen, who together report beneficial ownership of 3,900,000 shares of Enovis common stock. This represents 6.78% of the class, based on 57,562,603 shares outstanding as of May 1, 2026, as reported by Enovis. The shares are held by certain investment funds and/or accounts advised by Rubric Capital, including Rubric Capital Master Fund LP, which has the right to receive dividends and sale proceeds on more than 5% of the outstanding shares.
Both Rubric Capital and David Rosen report shared voting power and shared dispositive power over the 3,900,000 shares, with no sole voting or dispositive power. The filing states that it should not be construed as an admission that any reporting person is a beneficial owner of the reported shares for purposes of Section 13 of the Exchange Act.
Enovis Corporation reported higher sales and returned to operating profitability for the three and six months ended July 3, 2026. Net sales were $582,782 (Dollars in thousands) for the quarter and $1,171,933 (Dollars in thousands) year to date, up from $564,545 and $1,123,379 (Dollars in thousands) a year earlier. Operating income reached $17,413 (Dollars in thousands) for the quarter and $23,943 (Dollars in thousands) year to date, compared with operating losses in the prior periods. Higher income tax expense produced small net losses attributable to Enovis of $1,190 and $9,954 (Dollars in thousands), versus $36,739 and $92,705 (Dollars in thousands).
Prevention & Recovery revenue was broadly flat, while Reconstructive grew in both U.S. and international markets. Total Adjusted EBITDA rose to $104,321 and $207,888 (Dollars in thousands), with margins of 17.9% and 17.7%. Currency movements increased net sales by 1.0% for the quarter and 2.6% year to date. The effective tax rate exceeded 21% due to valuation allowances on U.S. deferred tax assets, non‑deductible expenses and U.S. taxation of international operations.
Operating activities generated $98,983 (Dollars in thousands) of cash in the first half, largely funding capital expenditures of $96,699 (Dollars in thousands). Cash and cash equivalents were $12,563 (Dollars in thousands), with total debt of $1,284,508 (In thousands), including a $670,559 term loan and $453,407 (In thousands) of senior unsecured convertible notes; $942 million remained available under the revolving credit facility. The company was in compliance with its credit agreement covenants and uses cross‑currency swaps and forward contracts to manage foreign exchange exposure.
Enovis Corporation reported second-quarter 2026 net sales of $582.8 million, up from $564.5 million a year earlier, driven by 7.5% reported growth in Reconstructive while Prevention & Recovery was roughly flat on a reported basis but grew 3.5% organically.
The company posted a small GAAP net loss of $1.0 million (0.2% of sales), but generated adjusted net income of $52.2 million and adjusted diluted EPS of $0.90. Adjusted EBITDA rose to $104.3 million, a 17.9% margin, compared with $91.2 million and a 16.2% margin in the prior-year quarter.
For 2026, Enovis reaffirmed guidance for revenue of $2.31–$2.37 billion with 4–6% organic growth, adjusted EBITDA of $425–$435 million, adjusted EPS of $3.52–$3.73, and free cash flow conversion of at least 25%.
BlackRock, Inc. has filed an amended Schedule 13G reporting its beneficial ownership of common stock of Enovis Corporation. BlackRock reports beneficial ownership of 9,181,052 shares of Enovis common stock, representing 15.9% of the class.
BlackRock has sole voting power over 9,087,287 shares and sole dispositive power over 9,181,052 shares, with no shared voting or dispositive power. The filing notes that this reflects securities beneficially owned, or deemed beneficially owned, by certain BlackRock business units. It also states that iShares Core S&P Small-Cap ETF has an interest in Enovis common stock representing more than five percent of the total outstanding common stock.
Enovis Corporation Schedule 13G/A amendment discloses beneficial ownership positions held by American Century entities and Stowers Institute. The filing lists American Century Investment Management, Inc. and American Century Companies, Inc. each holding 6,106,561 shares (10.6%), and American Century Capital Portfolios, Inc. holding 2,689,128 shares (4.7%), as reported on the cover pages. The registrants state their principal business address and identify voting and dispositive powers for each holder. The filing is an ownership disclosure amendment signed on 07/08/2026.
Ortiz Christine reported acquisition or exercise transactions in this Form 4 filing.
Enovis CORP director Christine Ortiz received an equity award of 846 shares of common stock. The shares were granted on June 30, 2026 at a stated price of $0.00 per share as a compensation-related award rather than a market purchase.
Following this grant, Ortiz directly holds 25,857 shares of Enovis common stock. This filing records a routine non-derivative stock award to a board member, with no associated open-market buying or selling activity.
Enovis CORP Chief Administrative Officer Oliver Engert reported an open-market purchase of 1,000 shares of common stock at $20.92 per share. Following this transaction, he directly owns 53,640 shares of Enovis common stock, increasing his personal stake in the company.
Engert Oliver reported acquisition or exercise transactions in this Form 4 filing.
Enovis Corp Chief Administrative Officer Oliver Engert reported an amended insider transaction showing a grant of 1,000 shares of common stock at $20.99 per share. The filing updates his direct holdings to 52,640 shares. The amendment corrects clerical errors in the original Form 4; no other changes were made.
Enovis CORP Chief Administrative Officer Oliver Engert bought additional company stock in the open market. He made two open-market purchases of Enovis common stock, totaling 1,200 shares. One trade was for 1,000 shares at $21.75 per share and another for 200 shares at $20.99 per share. These are direct ownership purchases, indicating he increased his personal stake in the company.
Enovis CORP Chief Administrative Officer Oliver Engert bought 1,000 shares of common stock in an open-market purchase at $23.00 per share on June 10, 2026. After this transaction, he directly owns 50,640 Enovis shares, modestly increasing his personal stake in the company.